Exelixis | EXEL - 资产



金融业
股票价格
USD
资产
USD 2.49B
现金及等价物
USD 281.45M
销售成本
USD 20.66M
流动资产
USD 1.25B
流动负债
USD 361.93M
债务
USD 165.93M
EBIT
USD 248.41M
EBITDA
USD 255.4M
员工
1.15K
EPS每股收益
USD 0.91
股本和储备
USD 1.84B
销售毛利
USD 608.03M
债务利息支出
USD 23.4M
利息收入
USD 14.21M
市值
USD 16.07B
净收入
USD 212.05M
营业费用
USD 380.28M
营业利润
USD 248.41M
普通股股本
USD 248.89M
PE价格收益
18.02
税前利润
USD 262.68M
销售收入
USD 628.69M
销售和管理费用
USD 147.63M
股票
USD 28.73M
贸易债权人
USD 39.06M
应收帐款人
USD 322.21M


资产 更改 日
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Akebia Therapeutics USD 349.66M 12.86M 2026-06
Amgen USD 95.64B 3.14B 2026-06
AstraZeneca USD 115.83B 1.82B 2026-06
Bayer EUR 107.29B 659M 2026-06
BioMarin Pharmaceutical USD 11.72B 3.13B 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Cytokinetics USD 1.92B 651.07M 2026-06
Eisai JPY 1.56T 108.98B 2026-06
Eli Lilly USD 142.28B 25.71B 2026-06
Exelixis USD 2.49B 99.36M 2026-06
Genmab DKK 12.52B 139M 2026-06
Glaxosmithkline GBP 62.87B 19.47B 2026-03
Incyte USD 7.87B 533.53M 2026-06
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
MacroGenics USD 345.41M 127.54M 2026-06
Merck USD 129.8B 1.12B 2026-06
Moderna USD 10.96B 527M 2026-06
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
Novartis USD 122.03B 3.5B 2026-06
Pfizer USD 201.13B 6.49B 2026-06
Puma Biotechnology USD 202.86M 7.95M 2025-09
Sanofi EUR 128.02B 1.22B 2026-03
Takeda JPY 15.66T 210.16B 2026-06
Ultragenyx Pharmaceutical USD 1.26B 32M 2026-06
Xencor USD 724.96M 11.89M 2026-06